西亚试剂 ：Combined MYC and P53 Defects Emerge at Medulloblastoma Re

发布时间：2025-08-04

We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, and all patients in this group died of rapidly progressive disease postrelapse. To study this interaction, we investigated a transgenic model of MYCN-driven medulloblastoma and found spontaneous development of Trp53 inactivating mutations. Abrogation of p53 function in this model produced aggressive tumors that mimicked characteristics of relapsed human tumors with combined P53-MYC dysfunction. Restoration of p53 activity and genetic and therapeutic suppression of MYCN all reduced tumor growth and prolonged survival. Our findings identify P53-MYC interactions at medulloblastoma relapse as biomarkers of clinically aggressive disease that may be targeted therapeutically.以上资料由西亚试剂：http://www.xiyashiji.com/提供

上一篇：山西焦化与永鑫集团签署合作协议
下一篇：西亚试剂：Crystal structure of the WOPR-DNA complex and implications